Shanghai Tofflon Science Tech - Asset Resilience Ratio
Shanghai Tofflon Science Tech (300171) has an Asset Resilience Ratio of 5.96% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Shanghai Tofflon Science Tech total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2024)
This chart shows how Shanghai Tofflon Science Tech's Asset Resilience Ratio has changed over time. See Shanghai Tofflon Science Tech book value and equity for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Shanghai Tofflon Science Tech's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is Shanghai Tofflon Science Tech worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥792.19 Million | 5.96% |
| Total Liquid Assets | CN¥792.19 Million | 5.96% |
Asset Resilience Insights
- Limited Liquidity: Shanghai Tofflon Science Tech maintains only 5.96% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Shanghai Tofflon Science Tech Industry Peers by Asset Resilience Ratio
Compare Shanghai Tofflon Science Tech's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Gan & Lee Pharmaceuticals Co Ltd
SHG:603087 |
Medical Instruments & Supplies | 9.08% |
|
Vizionfocus Inc.
TW:4771 |
Medical Instruments & Supplies | 5.07% |
|
Ansell Ltd
AU:ANN |
Medical Instruments & Supplies | 4.42% |
|
Nanosonics Ltd
AU:NAN |
Medical Instruments & Supplies | 51.82% |
|
SDI Ltd
AU:SDI |
Medical Instruments & Supplies | 6.36% |
|
Austco Healthcare Ltd
AU:AHC |
Medical Instruments & Supplies | 15.90% |
|
Trajan Group Holdings Ltd
AU:TRJ |
Medical Instruments & Supplies | 0.23% |
|
Osteopore Ltd
AU:OSX |
Medical Instruments & Supplies | 43.09% |
Annual Asset Resilience Ratio for Shanghai Tofflon Science Tech (2014–2024)
The table below shows the annual Asset Resilience Ratio data for Shanghai Tofflon Science Tech.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 3.44% | CN¥449.24 Million ≈ $65.74 Million |
CN¥13.07 Billion ≈ $1.91 Billion |
-0.79pp |
| 2023-12-31 | 4.23% | CN¥545.43 Million ≈ $79.81 Million |
CN¥12.90 Billion ≈ $1.89 Billion |
+2.12pp |
| 2022-12-31 | 2.11% | CN¥282.70 Million ≈ $41.37 Million |
CN¥13.38 Billion ≈ $1.96 Billion |
-11.94pp |
| 2021-12-31 | 14.06% | CN¥1.37 Billion ≈ $200.32 Million |
CN¥9.74 Billion ≈ $1.43 Billion |
-6.17pp |
| 2020-12-31 | 20.23% | CN¥1.33 Billion ≈ $194.76 Million |
CN¥6.58 Billion ≈ $962.83 Million |
-6.43pp |
| 2019-12-31 | 26.66% | CN¥1.39 Billion ≈ $203.16 Million |
CN¥5.21 Billion ≈ $762.18 Million |
+3.54pp |
| 2018-12-31 | 23.11% | CN¥1.08 Billion ≈ $158.55 Million |
CN¥4.69 Billion ≈ $686.01 Million |
+5.92pp |
| 2017-12-31 | 17.19% | CN¥750.46 Million ≈ $109.82 Million |
CN¥4.37 Billion ≈ $638.92 Million |
-3.58pp |
| 2016-12-31 | 20.77% | CN¥871.78 Million ≈ $127.57 Million |
CN¥4.20 Billion ≈ $614.30 Million |
+5.61pp |
| 2015-12-31 | 15.15% | CN¥615.56 Million ≈ $90.08 Million |
CN¥4.06 Billion ≈ $594.43 Million |
+13.83pp |
| 2014-12-31 | 1.32% | CN¥55.00 Million ≈ $8.05 Million |
CN¥4.17 Billion ≈ $609.91 Million |
-- |
About Shanghai Tofflon Science Tech
Tofflon Science and Technology Group Co., Ltd. engages in the research, development, production, sales, and services of pharmaceutical equipment in China and internationally. It operates through four segments: Biotechnology, Preparation Equipment, Engineering, and Food Engineering. The company offers technological research, such as cell technology, complex preparation, injection, and OSD laborato… Read more